HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25

Benzinga Newsdesk www.benzinga.com Neutral 69.6%

Neg 0% Neu 69.6% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Buy rating and announces Price Target of $25.